Browsing: Lilly
Eli Lilly reported third-quarter earnings and revenue well ahead of analysts’ expectations on Thursday, lifted by continued demand for its…
Amylin-based obesity drugs are emerging as a potential next step in treatment, with Eli Lilly and Novo Nordisk developing medicines…
Eli Lilly’s experimental obesity drug combination produced greater weight loss than its highest dose of tirzepatide alone in a 48-week…
Eli Lilly is widening its lead over Novo Nordisk in the obesity drug market, despite an ambitious attempt by the…
Subscribe to Updates
Subscribe to our newsletter and stay updated with the latest news and exclusive offers.
© 2026 Dispatch Times. All rights Reserved.